Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification

被引:14
|
作者
Arch, Jonathan R. S. [1 ]
Trayhurn, Paul [1 ]
机构
[1] Univ Buckingham, Clore Lab, Buckingham MK18 1EG, England
来源
FRONTIERS IN PHYSIOLOGY | 2013年 / 4卷
关键词
thermogenesis; energy expenditure; leanness; anti-obesity drug; genetically modified mouse; sympathomimetic; brown adipose tissue; leptin; BROWN ADIPOSE-TISSUE; BETA-ADRENOCEPTOR AGONIST; DIET-INDUCED OBESITY; INCREASES ENERGY-EXPENDITURE; SYMPATHETIC-NERVE ACTIVITY; ACTIVATED-RECEPTOR-GAMMA; RESTING METABOLIC-RATE; COLD-INDUCED INCREASE; FATTY-ACID OXIDATION; FOOD-INTAKE;
D O I
10.3389/fphys.2013.00064
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Many compounds and genetic manipulations are claimed to confer resistance to obesity in rodents by raising energy expenditure. Examples taken from recent and older literature, demonstrate that such claims are often based on measurements of energy expenditure after body composition has changed, and depend on comparisons of energy expenditure divided by body weight. This is misleading because white adipose tissue has less influence than lean tissue on energy expenditure. Application of this approach to human data would suggest that human obesity is usually due to a low metabolic rate, which is not an accepted view. Increased energy expenditure per animal is a surer way of demonstrating thermogenesis, but even then it is important to know whether this is due to altered body composition (repartitioning), or increased locomotor activity rather than thermogenesis per se. Regression analysis offers other approaches. The thermogenic response to some compounds has a rapid onset and so cannot be due to altered body composition. These compounds usually mimic or activate the sympathetic nervous system. Thermogenesis occurs in, but may not be confined to, brown adipose tissue. It should not be assumed that weight loss in response to these treatments is due to thermogenesis unless there is a sustained increase in 24-h energy expenditure. Thyroid hormones and fibroblast growth factor 21 also raise energy expenditure before they affect body composition. Some treatments and genetic modifications alter the diurnal rhythm of energy expenditure. It is important to establish whether this is due to altered locomotor activity or efficiency of locomotion. There are no good examples of compounds that do not affect short-term energy expenditure but have a delayed effect. How and under what conditions a genetic modification or compound increases energy expenditure influences the decision on whether to seek drugs for the target or take a candidate drug into clinical studies.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] A risk-benefit assessment of anti-obesity drugs
    Kolanowski, J
    DRUG SAFETY, 1999, 20 (02) : 119 - 131
  • [42] Comprehensive Review of Current and Upcoming Anti-Obesity Drugs
    Son, Jang Won
    Kim, Sungrae
    DIABETES & METABOLISM JOURNAL, 2020, 44 (06) : 802 - 818
  • [43] Regulation of food intake and the development of anti-obesity drugs
    Chen, Yue
    DRUG DISCOVERIES AND THERAPEUTICS, 2016, 10 (02): : 62 - 73
  • [44] EFFECT OF ANTI-OBESITY DRUGS ON LIPASE ACTIVITY INVITRO
    HOLMES, JH
    SAPEIKA, N
    ZWARENSTEIN, H
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1975, 10 (04): : 739 - 742
  • [45] A Risk-Benefit Assessment of Anti-Obesity Drugs
    Jaroslaw Kolanowski
    Drug Safety, 1999, 20 : 119 - 131
  • [46] Characteristics of diabetic patients starting anti-obesity drugs
    Willemen, M. J. C.
    Mantel-Teeuwisse, A. K.
    Straus, M. J. M.
    Leufkens, H. G. M.
    Egberts, A. C. G.
    DRUG SAFETY, 2007, 30 (10) : 968 - 968
  • [47] Anti-obesity drugs recalled from global market
    Ault, A
    LANCET, 1997, 350 (9081): : 867 - 867
  • [48] Use of anti-obesity drugs among college students
    de Carvalho e Martins, Maria do Carmo
    de Souza Filho, Manoel Dias
    Moura, Felipe Scipiao
    Ribeiro de Carvalho, Juliana de Sousa
    Mueller, Marina Costa
    Neves, Rebeka Valenca
    Mousinho, Patricia Coelho
    Lima, Iuri Paz
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2011, 57 (05): : 570 - 576
  • [49] Anti-obesity drugs: a review about their effects and their safety
    Derosa, Giuseppe
    Maffioli, Pamela
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 459 - 471
  • [50] Anti-obesity drugs: Use, mechanisms and clinical importance
    Adam, O
    Forth, W
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2001, 39 (06) : 232 - 238